CCM
XBIT icon

Cadian Capital Management’s XBiotech XBIT Stock Holding History

Cadian Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-139,829
Closed -$1.88M – 54
2016
Q3 		$1.88M Buy
+139,829
New +$2.05M 0.1% 47

Other funds holding XBIT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Cadian Capital Management's XBIT Position: Q4 2016 in Review

Cadian Capital Management sold out of XBiotech (XBIT) in Q4 2016, closing a stake of 139,829 shares — an estimated $1.88M sold.

Cadian Capital Management first reported a position in XBIT in Q3 2016 and held it in 1 quarter. The position peaked at $1.88M in Q3 2016. 49 funds tracked by Wall St. Rank hold XBIT as of Q4 2016.

  • Cadian Capital Management reported no remaining XBiotech position as of Q4 2016 after selling out during the quarter.
  • Cadian Capital Management sold 139,829 XBiotech shares in Q4 2016, an estimated $1.88M.
  • Cadian Capital Management first reported a position in XBiotech in Q3 2016 and held it in 1 quarter.
  • Cadian Capital Management's XBiotech position peaked at $1.88M in Q3 2016.
  • 49 funds tracked by Wall St. Rank held XBiotech as of Q4 2016.

Based on Cadian Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.